(UroToday.com) The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Shun Zhang discussing a phase 1 study of QLH12016, an androgen receptor PROTAC degrader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results